Le Lézard
Classified in: Health, Science and technology
Subject: TDS

@-Health Unveils the Future of E-health at CES 2018



AIX-EN-PROVENCE, France, December 8, 2017 /PRNewswire/ --

Stand 50023 - Espace Provence Alpes Côte d'Azur 

@-Health, a company specializing in e-cardiology, will be participating for the first time at the CES (Consumer Electric Show), the unmissable event of the world's high-tech, to be held from January 9-12, 2018 in Las Vegas. With the support of French Tech Aix-Marseille, the Aix-based company will present CardioNexion, the first connected medical device for the ultra-early detection and analysis, in real time and continuously, of all cardiovascular pathologies.

     (Logo: http://mma.prnewswire.com/media/617024/Health_Logo.jpg )

Cardiovascular disease is the leading cause of death worldwide according to WHO. In the face of this global public health challenge, @ -Health is setting its sights on being a leading player. By participating in CES 2018, the company intends to demonstrate the relevance of CardioNexion to US investors and find potential partners.

Recall that CardioNexion is a connected medical device that continuously monitors real-time cardiac activity by specialists in cardiology.

It can detect and prevent with certainty any pathology whose first sign is a change in heart rate: stroke, atrial fibrillation, heart failure, sudden infant death, influenza... well before the first symptoms appear.

CardioNexion is also a new tool for practitioners. Indeed, it allows the attending physician to prescribe appropriate treatment and control its effectiveness in real time: a world first!

Specifically, for the patient, the device is in the form of a T-shirt or bra with smart sensors that monitor in real time 24/24 - 365 / day / year many essential data for its health.

This totally ambulatory, non-invasive and autonomous device allows to have the same medical supervision as in an intensive care unit. Via the patient's smartphone, anonymized data, collected 24 hours a day, are sent to secure servers, where they will be analyzed using a proprietary algorithm. They are then transported to a surveillance platform where a team of cardiologists and intensive care unit nurses are ready to respond. If a problem is detected, the patient's doctor is notified. In the most serious cases, "911" is directly called.

FOR MORE INFORMATION 


These press releases may also interest you

at 21:32
HCP, Inc. (the "Company") announced today that it has agreed to sell 15,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 13,000,000 shares offered on a forward basis in connection with the...

at 21:00
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have...

at 20:50
Pascal Biosciences Inc. ("Pascal" or the "Company"), a drug discovery and development company, announced today it will host a year-end investor update webcast on Thursday, Dec. 17, 2018 at 1:30 p.m. PST. Dr. Patrick Gray, CEO of Pascal Biosciences,...

at 20:47
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and Oxford BioTherapeutics Ltd. ("OBT"), a clinical stage oncology...

at 20:42
Lawrence Theodore Petrakis, MD, FRCP(C) is recognized by Continental Who's Who as a Pinnacle Lifetime Member in the field of Psychiatry in recognition of his role as Psychiatrist at Lawrence Theodore Petrakis MD. Committed to providing patients...

at 20:42
Rev. Richard H. Klingeisen is recognized by Continental Who's Who as Pinnacle Professional of The Year for his notable work in the Healthcare and Pastoral Care fields.   Coordinator of Health Services at the Diocese of Green Bay, and Pastor at St....




News published on 7 december 2017 at 20:00 and distributed by: